Salidroside overcomes dexamethasone resistance in T‑acute lymphoblastic leukemia cells

The aim of the present study was to analyze whether the use of salidroside (SAL) could overcome dexamethasone (DEX) resistance in T‑acute lymphocytic leukemia cells. The human T‑ALL DEX‑resistant cell line, CEM‑C1 and the DEX‑sensitive cell line, CEM‑C7 were used in the current study. The proliferation inhibition rates in these cells, treated with SAL and DEX alone, and in combination were detected using a Cell Counting Kit‑8 assay, while the morphological changes of the cells were observed using an inverted microscope. Reverse transcription‑quantitative PCR was used to detect the mRNA expression levels of the c‑Myc and LC3 genes, while flow cytometry was used to detect the cell cycle distribution and the rate of apoptosis. In addition, western blot analysis was used to detect the protein expression levels of c‑Myc, BCL‑2, Bax, cleaved PARP and LC3. and acridine orange staining was used to detect the changes in acidic autophagy vesicles. It was found that SAL could effectively inhibit cell proliferation and induce apoptosis in the CEM‑C1 and CEM‑C7 cells. In addition, SAL promoted the induction of autophagy. The protein expression levels of c‑Myc in the CEM‑C1 cells were significantly higher compared with that in the CEM‑C7 cells. SAL downregulated the mRNA expression levels of the c‑Myc gene and protein in a dose‑dependent manner. This suggested that SAL could inhibit the proliferation of the CEM‑C1 and CEM‑C7 cells, induce apoptosis and autophagy and overcome DEX resistance in the CEM‑C1 cells. The mechanism may be associated with the downregulation of c‑Myc.